94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Yunxia Luo1,2†
Dongli Li1†
Yanfang Liao1†
Chuipu Cai1
Qihui Wu1
Hanzhong Ke3,4
Xinning Liu1
Huilin Li2
Honghai Hong5
Yumin Xu6
Qi Wang1,7*
Jiansong Fang1,7*
Shuhuan Fang1,7*- 1Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
- 2Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China
- 3Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States
- 4Department of Medicine, Harvard Medical School, Boston, MA, United States
- 5Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 6Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
- 7Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
A Corrigendum on
Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease
by Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J and Fang S (2020). Front. Pharmacol. 11:381. doi: 10.3389/fphar.2020.00381
In the published article, there was an error in Figure 8 as published. The Iba1 fluorescence image of the cortex and corresponding merged image in the KXS-L group was mistakenly displayed. The corrected Figure 8 and its caption appear below.
FIGURE 8
FIGURE 8. Kai-Xin-San (KXS) attenuates microglia activation in scopolamine (SCOP)-induced mice. Immunofluorescence analysis in the hippocampus (CA1) and cortex. Microglia were stained with anti-Iba-1 (red) and the nuclei were stained with DAPI (blue). Scale bar: 50 mm. Con, control group; SCOP, scopolamine; KXS-L, low-dose Kai-Xin San (1.4 g/kg); KSX-H, high-dose Kai-Xin San (2.8 g/kg); Don, donepezil.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: systems pharmacology, Kai-Xin-San, Alzheimer’s disease, cholinergic system, neuroinflammation
Citation: Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J and Fang S (2023) Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease. Front. Pharmacol. 14:1239060. doi: 10.3389/fphar.2023.1239060
Received: 23 August 2023; Accepted: 22 September 2023;
Published: 06 October 2023.
Edited and reviewed by:
Wei Peng, Chengdu University of Traditional Chinese Medicine, ChinaCopyright © 2023 Luo, Li, Liao, Cai, Wu, Ke, Liu, Li, Hong, Xu, Wang, Fang and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qi Wang, d2FuZ3FpQGd6dWNtLmVkdS5jbg==; Jiansong Fang, ZmFuZ2pzQGd6dWNtLmVkdS5jbg==; Shuhuan Fang, ZmFuZ3NodWh1YW5AZ3p1Y20uZWR1LmNu
†These authors have contributed equally to this work